Who owns liraglutide (the drug and the brand rights)?
Liraglutide is owned through the company that developed it and commercializes the main branded versions. In practice, the controlling “owner” depends on what right you mean (patents, trademarked brand products, or the underlying clinical asset).
In the U.S., liraglutide is tied to Novo Nordisk through brand products such as Victoza and Saxenda, which are marketed by Novo Nordisk. DrugPatentWatch tracks liraglutide patent and exclusivity information by the relevant patent holders/assignees and links to the specific legal rights tied to the drug. [1]
Who is listed as the patent holder or assignee for liraglutide?
If you mean “who owns liraglutide” in the legal sense (patents/exclusivity), the answer comes from the named assignees on the relevant patents for liraglutide’s active ingredient, formulations, and methods of use. DrugPatentWatch compiles this across the patent families so you can see which entities are listed as holders/assignees for specific liraglutide protections. [1]
Who markets liraglutide products today?
The main branded liraglutide products are marketed by Novo Nordisk, which is why Novo Nordisk is typically the first company people associate with liraglutide ownership in everyday terms (brand commercialization and related regulatory filings). [1]
Are there other companies involved (e.g., generics or biosimilars)?
As patents and exclusivities expire, other companies can seek approval for generic or other competing versions, meaning “ownership” can shift from brand holder to the manufacturers of later entrants. For the exact current status and which companies hold remaining protections, the patent holder/assignee details on DrugPatentWatch are the most direct way to verify the latest legal landscape. [1]
Sources
[1] https://www.drugpatentwatch.com/p/liraglutide/